Ethics-Governance: Article: eMJA: The aromatase inhibitors in early breast cancer: who, when and why?

Articles indexes: a \| b \| c \| d \| e \| f \| g \| h \| i \| j \| k \| l \| m \| n \| o \| p \| q \| r \| s \| t \| u \| v \| w \| x \| y \| z \| other

Article - Abstract. To view full article click on the article title.
eMJA: The aromatase inhibitors in early breast cancer: who, when and why? It is reassuring to be informed that the company concerned had no role in the content of the article. However, is it wise and reasonable and, indeed, necessary for a medical oncology registrar to be financially rewarded by a pharmaceutical company for writing an article published in The Medical Journal of Australia about therapeutic products, one of which was developed and is now marketed by that company? Two other authors and reviewers and editorial staff were involved in this otherwise excellent article. I commend Nordman for her openness and declaration. However, I question the role of the pharmaceutical industry in rewarding medical authors in this way. Competing interests: Since 1992, I have received three “travel grants” from pharmaceutical companies — two for international meetings and one for a product launch. One company was involved with an aromatase inhibitor. Nordman IC, Spillane AJ, Hamilton AL. The aromatase inhibitors in early breast cancer: who, when and why? Med J Aust 2005; 183: 24-27. Full Article: http://www.mja.com.au/public/issues/184_01_020106/letters_020106_fm-4.html


2006 Ethics-Governance.com